Non Hodgkin Lymphoma Clinical Trial
Use of Topotecan in Patients With Refractory Acute Leukemia
Summary
The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone and etoposide) as well as a newer drug that has also been shown to be effective (topotecan).
Full Description
The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone and etoposide) as well as a newer drug that has also been shown to be effective (topotecan).
Eligibility Criteria
Inclusion Criteria:
Patients in the following disease categories will be considered eligible for this study:
Any acute leukemia beyond an initial attempt to induce a remission or after relapse
Chronic Myelogenous Leukemia in Blast Phase
Refractory Multiple Myeloma
Refractory non-Hodgkin's and Hodgkin's Lymphoma
Patients must be more than 14 days beyond prior myelotoxic chemotherapy
Several other eligibility criteria apply.
Exclusion Criteria:
None
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Gainesville Florida, 32608, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.